**Quarterly activities report for January – March 2024**

The quarterly activities include details of monitoring and compliance activities by the Office of the Gene Technology Regulator (OGTR) during the quarter.

**Monitoring of GMO Dealings involving Intentional Release (DIR)**

During the quarter the OGTR did not inspect any GM plant field trial sites.

**Monitoring of GMO Dealings Not involving Intentional Release (DNIR), certified facilities and DIR clinical and veterinary trials**

During the quarter, the OGTR inspected **four** organisations holding certified facilities (**Table 1**) and **four** organisations holding a DNIR or DIR licence (**Table 2**).

Table 1 – Summary of organisations and facility types that the OGTR inspected for the January – March 2024 quarter.

| **Organisation** | **Physical Containment (PC) level**  | **Number of facilities monitored** |
| --- | --- | --- |
| The University of Adelaide | PC2 Aquatic Facility PC2 Laboratory | 121 |
| The University of Melbourne | PC2 Animal Facility PC2 Invertebrate Facility PC2 LaboratoryPC2 Plant Facility | 41202 |
| The University of Queensland | PC2 Laboratory | 5 |
| University of South Australia | PC2 Animal Facility PC2 Aquatic Facility PC2 Laboratory | 112 |
| **Total** |  | **58** |

Table 2 – Summary of inspection activities for DNIR licences, DIR clinical and veterinary trial licences for the January – March 2024 quarter.

| **Licence holder** | **Licence number**  |
| --- | --- |
| Avance Clinical Pty Ltd | DIR-184 |
| Novotech (Australia) Pty Limited | DNIR-678 |
| University of South Australia | DNIR-529 |
| The University of Melbourne  | DNIR-525 |

**Practice Reviews, Audits and Investigations**

The Monitoring and Compliance section may initiate practice reviews in response to observations made during earlier monitoring activities, or to follow up incident reports or to assess the effectiveness of systems used by licence holders and IBC(s). The objective is to determine if licence conditions can be, and are being, effectively implemented. No practice reviews were undertaken during the quarter.

During the January – March 2024 quarter the OGTR did not conduct any audit activities or investigations.

**Monitoring and Compliance Findings**

Findings from routine monitoring, auditing and investigations, and related enforcement activities, are provided in the Regulator’s Annual Report in accordance with section 136 of the *Gene Technology Act 2000*.